Horphag Research, Geneva, Switzerland.
Phytother Res. 2014 Mar;28(3):348-62. doi: 10.1002/ptr.5019. Epub 2013 Jun 15.
The present review provides an update of the biological profile of Pycnogenol in the light of its use in the treatment of chronic venous insufficiency (CVI) and related venous disorders such as deep vein thrombosis (DVT), post-thrombotic syndrome, long haul air-travel-related leg oedema, venous ulcers and acute haemorrhoids. Pycnogenol is a French maritime pine bark extract produced from the outer bark of Pinus pinaster Ait. subsp. atlantica. Its strong antioxidant, anti-inflammatory and vasodilator activities, antithrombotic effects and collagen stabilizing properties make it uniquely able to target the multi facet pathophysiology of CVI and related venous disorders. Clinical studies have shown that it can reduce oedema of the legs in CVI, reduce the incidence of deep venous thrombosis during long haul flights and enhance the healing of venous ulcers and haemorrhoidal episodes by topical application and/or oral administration. This review highlights clinical research findings on the safety, compliance and efficacy of Pycnogenol, including its use in combination products.
本综述根据其在治疗慢性静脉功能不全（CVI）及相关静脉疾病（如深静脉血栓形成（DVT）、血栓后综合征、长途航空旅行相关腿部水肿、静脉溃疡和急性痔）中的应用，更新了碧萝芷的生物学特征。碧萝芷是一种源自法国沿海松树皮的提取物，由 Pinus pinaster Ait. subsp. atlantica 的外树皮制成。其强大的抗氧化、抗炎和血管扩张活性、抗血栓作用以及胶原蛋白稳定特性，使其能够针对 CVI 和相关静脉疾病的多方面病理生理学进行靶向治疗。临床研究表明，它可以减轻 CVI 患者腿部的水肿，降低长途飞行中深静脉血栓形成的发生率，并通过局部应用和/或口服给药来促进静脉溃疡和痔发作的愈合。本综述强调了关于碧萝芷安全性、顺应性和疗效的临床研究结果，包括其在联合产品中的应用。
